Free Trial
NASDAQ:ABMD

Abiomed (ABMD) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$381.02
$381.02
50-Day Range
$377.20
$381.30
52-Week Range
$219.85
$381.99
Volume
258 shs
Average Volume
611,028 shs
Market Capitalization
$17.18 billion
P/E Ratio
65.47
Dividend Yield
N/A
Price Target
N/A
ABMD stock logo

About Abiomed Stock (NASDAQ:ABMD)

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

ABMD Stock News Headlines

Exposed: 3 CENT Crypto to Explode June 24th?
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…
Tiny Defense Firm Set for Huge Gains with New US Contract
One tiny defense firm just won a groundbreaking US military contract… That could hand early investors gains of up to 35,960%.
FDA warns Abiomed over device classification
This Big Pharma Stock Is a Clear Buy in 2023
3 Powerhouse Stocks to Buy in 2023
See More Headlines
Receive ABMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abiomed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/27/2021
Today
7/22/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ABMD
CUSIP
00365410
Employees
2,003
Year Founded
1981

Profitability

Net Income
$136.51 million
Pretax Margin
31.76%

Debt

Sales & Book Value

Annual Sales
$1.03 billion
Cash Flow
$5.09 per share
Book Value
$33.03 per share

Miscellaneous

Free Float
43,964,000
Market Cap
$17.18 billion
Optionable
Optionable
Beta
1.40

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

Key Executives


ABMD Stock Analysis - Frequently Asked Questions

How were Abiomed's earnings last quarter?

Abiomed, Inc. (NASDAQ:ABMD) posted its quarterly earnings data on Wednesday, October, 27th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.05. The business's revenue was up 18.3% on a year-over-year basis.
Read the conference call transcript
.

What is Michael R. Minogue's approval rating as Abiomed's CEO?

96 employees have rated Abiomed Chief Executive Officer Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among the company's employees.

Does Abiomed have any subsidiaries?

The following companies are subsidiaries of Abiomed: ECP Entwicklungsgesellschaft mbH, Impella Cardiosystems, ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, and others.

What other stocks do shareholders of Abiomed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG) and Block (SQ).

This page (NASDAQ:ABMD) was last updated on 7/22/2024 by MarketBeat.com Staff

From Our Partners